Study of Adding High-Flow Oxygen Therapy to Regular Long-Term Oxygen Treatment for Adults with Severe COPD or Interstitial Lung Disease using the Lumis HFT Device

What this Trial Is About

Researchers are evaluating the effect of adding high-flow oxygen therapy using the Lumis HFT device to regular low-flow oxygen therapy in people with long-term oxygen therapy LTOT for chronic obstructive pulmonary disease COPD or interstitial lung disease ILD. This registry-based, randomized, controlled clinical trial aims to improve evidence-based treatment for patients with chronic respiratory failure, who face a high risk of adverse events and mortality. Participants will be randomly assigned to either receive added high-flow oxygen therapy during nighttime and at their discretion during the day alongside their usual low-flow oxygen therapy, or to continue with standard care using low-flow oxygen therapy alone. The study will last up to one year and is based on data from the Swedish National Registry for Respiratory Failure Swedevox in collaboration with the Swedish Respiratory Society. During the study, researchers will monitor time to first hospitalization or death from any cause over one year as the primary outcome. Secondary outcomes include hospitalization rates, intensive care admissions, mortality rates, exacerbations, quality of life, health status, breathlessness, sleep quality, physical activity, nasal symptoms, and adverse events at several time points. Participant assessments will include regular follow-ups over the year to gather these data and evaluate the impact of the added therapy.

Effect of HIgh-flow Therapy in Long-term Oxygen Therapy